A federal judge has blocked the US government from placing Chinese biotech firm WuXi AppTec on the Pentagon's list of companies with alleged ties to China's military, granting the company a significant legal victory in a dispute that underscores escalating US-China tensions in the life sciences sector.

The ruling follows WuXi AppTec's aggressive legal challenge to the Pentagon's June 8 designation under Section 1260H. The company filed a lawsuit on June 11 in the US District Court for the District of Columbia and requested a preliminary injunction on June 29, arguing that the classification lacked both legal and factual basis.

Section 1260H and the Stakes for WuXi AppTec

Section 1260H serves as the Pentagon's mechanism for identifying companies it believes have connections to China's military apparatus. While inclusion on the list does not formally ban American firms from conducting business with designated entities, it effectively renders such relationships commercially untenable.

For WuXi AppTec, the designation risked triggering restrictions under the Biosecure Act provisions incorporated into the FY2026 National Defense Authorization Act. These provisions could sever the company's access to US federal procurement and funding opportunities — a potentially critical setback for a firm that derives approximately 70% of its revenue from the US market.

The Pentagon's rationale was based on indirect ownership links to China's State-owned Assets Supervision and Administration Commission (SASAC) and alleged affiliations with the People's Liberation Army (PLA). WuXi AppTec has categorically denied any military connections, stating that it does not provide services to the PLA in any capacity.

Hong Kong-listed shares of WuXi AppTec fell roughly 5% following the initial designation, reflecting immediate market concerns about the company's continued access to its most important revenue source.

Broader Context and Ongoing Legal Proceedings

WuXi AppTec is one of the world's largest contract development and manufacturing organizations (CDMOs), providing outsourced research, development, and manufacturing services to pharmaceutical and biotechnology companies worldwide. The company operates major facilities in the United States, and its role in the global drug development pipeline means that restrictions on its operations could affect Western drugmakers that depend on CDMO partners for clinical trial materials and commercial drug production. The company has stated its intention to pursue every available legal avenue to contest the designation.

WuXi AppTec is not the only Chinese biotech firm to face US government scrutiny. Affiliates such as WuXi Biologics and other Chinese genomics and life sciences companies, including those linked to BGI, have also been designated or targeted by US restrictions in recent years, part of a pattern of escalating measures across the sector.

Congressional efforts targeting WuXi entities date back to at least 2024, when lawmakers raised concerns about Chinese biotech firms' access to sensitive American health data and their potential roles in China's military-civil fusion strategy. The Biosecure Act was partly designed with WuXi in mind, reflecting a broader legislative push to decouple critical biotech supply chains from Chinese companies.

The judge's intervention does not constitute a final ruling in WuXi AppTec's favor. Rather, it indicates that the court found sufficient merit in the company's arguments to halt the designation's effects while the full case proceeds through the judicial process. The outcome of the case is likely to be closely watched by other designated Chinese firms and by US pharmaceutical companies evaluating their CDMO relationships in light of the shifting regulatory landscape.